Jubilant Pharmova Ltd

NSE: JUBLPHARMA · BSE: 530019 · Pharmaceuticals & Biotechnology · 4 announcements

Share price: ₹1,071.95
Market cap: ₹17,074 Cr
Revenue (annual): ₹8,280 Cr
Net profit (annual): ₹398.5 Cr
P/E (TTM): 48.5×Sector 50.4×
Promoter holding: 47.68%+0.00% QoQ
FII holding: 15.87%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Financial Results 2 Earnings Call 1 Business Update 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

4 announcements

11 Sep 2026 19:42 IST BSE

Business Update

Jubilant Pharmova Business Update

Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.

Read the filing ↗

10 Aug 2026 19:15 IST BSE

Financial Results

Jubilant Pharmova Q1 FY27 Results: Net Profit ₹56.4 Cr, Down 45.0% YoY

Jubilant Pharmova Ltd reported revenue from operations of ₹2,229 Cr (+17.3% YoY) and net profit of ₹56.4 Cr (-45.0% YoY) for Q1 FY27.

Key figure: Net profit ₹56.4 Cr · -45.0% YoY

Open full results → Read the filing ↗

27 May 2026 20:24 IST BSE

Earnings Call

Jubilant Pharmova Earnings Call: Key Takeaways

Jubilant Pharmova Q4FY26 revenue grew 19% YoY to ₹2,290 Cr. FY26 revenue reached ₹8,280 Cr (up 14%) driven by CDMO Sterile Injectables and Radiopharma growth.

Open call summary → Read the filing ↗

22 May 2026 14:26 IST BSE

Financial Results

Jubilant Pharmova Q4 FY26 Results: Net Profit ₹119.3 Cr, Down 21.2% YoY

Jubilant Pharmova Ltd reported revenue from operations of ₹2,290 Cr (+18.7% YoY) and net profit of ₹119.3 Cr (-21.2% YoY) for Q4 FY26.

Key figure: Net profit ₹119.3 Cr · -21.2% YoY

Open full results → Read the filing ↗